Genetic Stability Testing for Cell Bank Release

Q: How to set copy number acceptance criteria?

Establish baseline from at least 3 GMP batches of MCB, then evaluate EOPC variation. Industry reference: variation ≤±20-30% or RSD ≤25% (medium-high copy) / ≤35% (low copy). Phase I acceptance criteria may be more flexible, but must be scientifically justified.

Overview Methods Regulatory Customization Contact Us FAQ

Overview

Genetic stability testing is a core quality control service for cell substrate release. It assesses the genetic integrity of recombinant production cell lines throughout their lifecycle, ensuring consistency between the master cell bank (MCB) and end-of-production cells (EOPC).

Per ICH Q5B, regulatory authorities require analysis at both MCB and EOPC time points to demonstrate genetic stability. The coding sequence of the expression construct must be confirmed, the transgene copy number must be determined, and the integrity/integration pattern must be demonstrated by restriction mapping. For genetically modified cell therapy products (e.g., CAR-T), integration site analysis is an essential component.

Creative Biogene's service covers four core modules: target gene sequencing, Southern blot, copy number analysis, and integration site analysis.

Four Testing Modules

Method	Target	Applicable Scenarios	Regulatory Status
Target gene sequencing (Sanger/NGS)	Coding sequence integrity	MCB/WCB/EOP routine release	ICH Q5B mandatory
Southern blot	Integration pattern and structural integrity	MCB/EOP integration confirmation	ICH Q5B mandatory
Copy number analysis (qPCR/ddPCR)	Transgene copy number	MCB/WCB/EOP release	ICH Q5B mandatory
Integration site analysis (NGS)	Site mapping + clonal tracking	CAR-T, integrating vectors	Mandatory for integrating vectors

Regulatory

Guideline	Key Requirement
ICH Q5B	Analyze cell substrate at MCB and EOPC; confirm coding sequence, copy number, restriction map integrity, and integration pattern.
ICH Q5D	Verify coding sequence identity of expression constructs.
WHO TRS 978 Annex 3	Determine copy number and, if necessary, chromosomal integration sites.
FDA 1993 PTC	Classic guidance for cell line characterization; still an important reference.

Testing requirements by cell bank type:

Cell Bank Type	Target Gene Sequencing	Southern Blot	Copy Number	Integration Site (CAR-T)
MCB	Mandatory	Mandatory	Mandatory	Mandatory for integrating vectors
WCB	Usually tested	–	Usually tested	–
EOPC	Mandatory	Mandatory	Mandatory	Mandatory for integrating vectors

Actual criteria must be risk-based and justified. For Phase I IND, stage-appropriate criteria with scientific rationale are acceptable.

Customization

Cell-type-specific panels: CHO, HEK293, Vero, NS0; custom copy number primers, probes, and sequencing designs.
CAR-T integration site analysis: Full LAM-PCR/NGS enrichment, bioinformatics, clonal abundance tracking, proto-oncogene enrichment assessment.
Passage stability studies: Include multiple intermediate passage levels (e.g., P5, P10, P15) to construct a full genetic stability decay curve.
Strategy consulting: ICH Q5B-aligned testing strategy and acceptance criteria based on cell substrate characteristics and clinical stage.
NGS integrated assessment: Single NGS approach for sequence verification, integration pattern analysis, and copy number estimation.

Contact Us

For a customized genetic stability testing strategy, method validation, or IND/BLA submission support for your cell line, contact Creative Biogene's technical team.

FAQ

Q1: How to choose between Sanger and NGS sequencing?

A: Sanger is suitable for routine release (high accuracy, low cost, ≥5% mutation detection). NGS is suitable for deep characterization and low-frequency mutation screening (≥1% sensitivity). Recommendation: Sanger for routine release; NGS for long-term passage stability studies.

Q2: Why is integration site analysis mandatory for CAR-T products?

A: Vector integration is semi-random. Integration site analysis is required to assess insertional mutagenesis risk (integration near proto-oncogenes), track clonal dynamics, and support long-term safety evaluation. Recent NEJM reports of secondary T-cell lymphomas after CAR-T therapy further highlight its importance.

Q3: How to choose between qPCR and ddPCR for copy number analysis?

A: qPCR is suitable for routine release (high throughput, lower cost). ddPCR provides absolute quantitation without a standard curve and offers better precision at low copy numbers. Recommendation: qPCR for routine release; ddPCR for IND critical batches or low-copy samples (<10 copies/genome).

Q4: How to set copy number acceptance criteria?

A: Establish baseline from at least 3 GMP batches of MCB, then evaluate EOPC variation. Industry reference: variation ≤±20-30% or RSD ≤25% (medium-high copy) / ≤35% (low copy). Phase I acceptance criteria may be more flexible, but must be scientifically justified.

* For research use only. Not intended for any clinical use.

Quick Inquiry